3 results
Approved WMOCompleted
The primary objective of this study is to obtain clinical proof of principle that the addition of a PgP/BCRP inhibitor increases CNS concentrations of tyrosine kinase inhibitors by inhibition of drug efflux transporter function in the blood brain…
Approved WMOCompleted
To determine the pharmacokinetic properties of a new elacridar formulation
Approved WMOCompleted
Primary Objective: To answer the following question: Does the extended approach (defined as uroflowmetry and bladder scan after the first consultation, followed by a check-up in month 3 of the male patient over 50 years of age first presenting with…